Clinical Trial: Mapping analysis of disease-specific quality of life measurement and preference-based measurement in adult patients with attention deficit hyperactivity disorder (Japan)

Tokyo, Oct. 4 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000063152) titled 'Mapping analysis of disease-specific quality of life measurement and preference-based measurement in adult patients with attention deficit hyperactivity disorder' on Oct. 4.

Study Type: Observational

Primary Sponsor: Institute - Otsuka Pharmaceuticals Co., Ltd

Condition: Condition - Attention deficit/hyper activity disorder Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - Conduct a questionnaire survey focusing on adults with attention deficit hyperactivity disorder (ADHD) and mapping analysis using the Adult ADHD Quality of Life Scale (AAQoL), a disease-specific quality of life (QOL) measure, to preference-based measures including the EuroQol 5 dimensions 5-level (EQ-5D-5L) and Health Utilities Index Mark 3 (HUI3). Basic objectives2 - Others

Eligibility: Age-lower limit - 18 years-old

Gender - Male and Female Key inclusion criteria - Have a confirmed diagnosis of attention-deficit/hyperactivity disorder (ADHD). Be currently receiving medication for ADHD. Be aged 18 years or older and younger than 58 years at the time of participation. Be residing in Japan. Provide informed consent and voluntarily agree to participate in this study. Key exclusion criteria - Individuals who are unable to provide informed consent or participate in the study due to insufficient Japanese language proficiency. Individuals who are unable to complete the survey by themselves. Individuals whose sex reported in the survey is inconsistent with the sex recorded in the panel registration data, excluding responses of "Other" or "Prefer not to answer." Individuals whose age reported in the survey is inconsistent with the age recorded in the panel registration data; discrepancies of less than 2 years will be considered acceptable. Target Size - 400

Recruitment Status: Recruitment status - No longer recruiting Date of protocol fixation - 2025 Year 09 Month 04 Day Date of IRB - 2025 Year 09 Month 04 Day Anticipated trial start date - 2025 Year 11 Month 01 Day Last follow-up date - 2026 Year 04 Month 13 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067515

Disclaimer: Curated by HT Syndication.